Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas - von Minckwitz, G; Harder, S; Hövelmann, S (Breast Cancer Res, 2005)
et al.